-
Endpoints News3 months ago
AnaptysBio spins out biotech operations; Affibody’s data in hidradenitis suppurativa
Plus, news about Zenas and Ysios Capital: 🌀 AnaptysBio’s spinout: The independent public company, called First Tracks Biotherapeutics, is expected to start trading on April 20....
-
BioPharma Dive – AI / Data3 months agoNovartis targets Xolair successor in buyout of startup Excellergy
Worth up to $2 billion, the deal is centered around a drug that could lead to faster and more complete control of allergic conditions than Novartis...
-
Endpoints News3 months ago
FDA approves Rocket’s gene therapy for ultra-rare immune disease
A rare disease gene therapy from Rocket Pharmaceuticals has garnered FDA approval after an earlier rejection for manufacturing problems. The FDA on Thursday granted accelerated approval...
-
GEN – Genetic Engineering & Biotechnology News3 months agoStem Cells at the Frontier: Breakthroughs, Barriers, and What’s Next
Register Now Panelists: Robert Signer, PhD Associate Professor, MedicineUniversity of California San Diego View Bio Panelist Robert Signer, PhD Robert Signer, PhD, is a stem cell...
-
Fierce Biotech3 months ago
Scientists turn pig semen extract into eye drops that kill cancer in mice
The human eye is like an immunological fortress, with its ability to exclude unwanted intruders a boon when preventing infection but a burden when trying to...
-
STAT News – Biotech3 months agoSTAT+: China’s biotech boom is rewriting everything
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. The NIH’s foreign subaward crackdown...
-
GEN – Genetic Engineering & Biotechnology News3 months ago
Blocking TIE2 Protein May Prevent Blood Vessel Defects in the Brain
Scientists from the Perelman School of Medicine at the University of Pennsylvania and their colleagues have identified a cell surface receptor protein called TIE2 as a...
-
STAT News – Biotech3 months agoThe impact of NIH restrictions on foreign institutions
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning. We’re down to the final four...
-
STAT News – Biotech3 months agoSTAT+: Up and down the ladder: The latest comings and goings
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send...
-
Endpoints News3 months ago
FDA approves Novo Nordisk’s once-weekly insulin
The FDA finally greenlit Novo Nordisk’s once-weekly insulin for type 2 diabetes, making it the first US-approved longer-acting alternative to daily basal treatment for this indication....
Amgen shores up Tavneos’ FDA defense with Duke data analysis
